Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Lei Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4163-2541; OpenAlex author ID A5100415060, A5130146398, A5135352913, A5136361181; NIH RePORTER profile ID 9387212. Sources: OpenAlex.

Their work

Papers
148 (first author 10, last author 42)
Trials
0
Grants
4
Labs led
2
Collaborators
361
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 10 papers · 2014: 4 papers, 1 grant · 2015: 7 papers · 2016: 8 papers · 2017: 12 papers · 2018: 11 papers · 2019: 16 papers · 2020: 8 papers · 2021: 12 papers · 2022: 20 papers · 2023: 8 papers, 1 grant · 2024: 11 papers · 2025: 10 papers, 1 grant · 2026: 6 papers, 1 grant

Papers 50 of 148

  1. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Last author DOI 10.1038/s41467-026-69294-3↗
  2. CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. Co-author DOI 10.1038/s41467-026-75132-3↗
  3. Twist1 overexpression models an aggressive subtype of pancreatic ductal adenocarcinoma in vivo. Co-author DOI 10.1038/s41684-026-01729-2↗
  4. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  5. Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fimmu.2026.1715761↗
  6. Widespread Hyperalgesia Predicts Mortality in Pancreatic Adenocarcinoma Co-author DOI 10.64898/2026.05.19.26353594↗
  7. CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial. Co-author DOI 10.1016/j.isci.2024.111569↗
  8. Pancreatic adenocarcinoma patients with pain have abnormal central pain processing. Co-author DOI 10.1016/j.pan.2025.04.010↗
  9. The tumour microenvironment in pancreatic cancer - new clinical challenges, but more opportunities. Last author DOI 10.1038/s41571-025-01077-z↗
  10. The Organ-Specific Prognostic Value of TP53 Mutations in Pancreatic Cancer Patients with Oligometastasis Following Surgical Resection. Co-author DOI 10.1097/sla.0000000000006823↗
  11. Comparison of Shared Class I HLA-Bound Noncanonical Neoepitopes between Normal and Neoplastic Tissues of Pancreatic Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-24-2251↗
  12. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
  13. Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments. Last author DOI 10.1186/s40164-025-00607-w↗
  14. Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer. Last author DOI 10.1186/s40364-024-00721-7↗
  15. Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. Co-author DOI 10.1200/po-24-00494↗
  16. Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Co-author DOI 10.18632/oncotarget.28739↗
  17. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Co-author DOI 10.1016/j.ccell.2024.03.009↗
  18. The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s43018-023-00697-7↗
  19. Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies. Co-author DOI 10.1080/1744666x.2024.2348605↗
  20. Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic resp… Co-author DOI 10.1101/2024.09.22.613714↗
  21. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Last author DOI 10.1126/sciadv.adk1827↗
  22. Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming. Last author DOI 10.1126/sciadv.adp0684↗
  23. Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Du… Co-author DOI 10.1158/0008-5472.can-23-1660↗
  24. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. Co-author DOI 10.1158/1078-0432.ccr-23-3841↗
  25. Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. Last author DOI 10.1186/s13045-024-01576-z↗
  26. In vivo bioluminescence tomography-guided system for pancreatic cancer radiotherapy research. Co-author DOI 10.1364/boe.523916↗
  27. The impact of KRAS mutations on the clinical outcome and immune response following immunotherapy for pancreatic cancer. Last author DOI 10.21037/apc-24-2↗
  28. Effectiveness of the nutrition referral system in a multidisciplinary pancreatic cancer clinic. Co-author DOI 10.1007/s00520-023-07795-3↗
  29. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05476-w↗
  30. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Last author DOI 10.1016/j.canlet.2023.216366↗
  31. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Last author DOI 10.1038/s41467-023-39196-9↗
  32. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2023.06.037↗
  33. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
  34. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a … Co-author DOI 10.3389/fonc.2023.1250136↗
  35. The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15041252↗
  36. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  37. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-022-06667-x↗
  38. Giant obscurin regulates migration and metastasis via RhoA-dependent cytoskeletal remodeling in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.11.016↗
  39. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Last author DOI 10.1016/j.canlet.2022.215722↗
  40. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Last author DOI 10.1016/j.ccell.2022.10.001↗
  41. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
  42. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Co-author DOI 10.1053/j.gastro.2022.06.027↗
  43. The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. Co-author DOI 10.1067/j.cpradiol.2022.05.001↗
  44. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. Last author DOI 10.1084/jem.20211631↗
  45. Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture Co-author DOI 10.1101/2022.07.14.500096↗
  46. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  47. A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pan… Co-author DOI 10.1186/s13014-022-02145-9↗
  48. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  49. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  50. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… Co-author DOI 10.1245/s10434-021-11202-8↗

Grants 4

  1. Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial R01CA197296↗
  2. Administrative Core P01CA247886↗
  3. Interrogate the interaction between tumor cells and nerves in the tumor microenvironment of pancreatic cancer R01CA169702↗
  4. Dissecting the mechanisms of immune tolerance within the pancreatic tumor's micro K23CA148964↗

Closest collaborators

The 25 strongest of 361 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elizabeth M. Jaffee · 44 shared papers, 2 shared grants, 2011–2026 · strength 5.73
  2. Jin Peng He · 47 shared papers, 2013–2026 · strength 5.65
  3. Daniel A. Laheru · 49 shared papers, 2011–2026 · strength 4.60
  4. Amol Kumar Narang · 33 shared papers, 2012–2026 · strength 4.05
  5. Richard Andrew Burkhart · 27 shared papers, 2018–2026 · strength 3.44
  6. Joseph M. Herman · 39 shared papers, 2012–2026 · strength 3.42
  7. Dung Thi Le · 26 shared papers, 1 shared grant, 2011–2026 · strength 2.96
  8. Christopher Lee Wolfgang · 31 shared papers, 2012–2022 · strength 2.14
  9. Ana De Jesus‐Acosta · 22 shared papers, 2012–2026 · strength 2.05
  10. Keyu Li · 13 shared papers, 2020–2025 · strength 1.90
  11. Alex B. Blair · 19 shared papers, 2017–2024 · strength 1.90
  12. Robert A. Anders · 20 shared papers, 2011–2026 · strength 1.89
  13. Colin Hill · 12 shared papers, 2021–2023 · strength 1.83
  14. Christopher L. Wolfgang · 18 shared papers, 2015–2024 · strength 1.80
  15. Eric Scott Christenson · 4 shared papers, 1 shared grant, 2024–2026 · strength 1.80
  16. Abhinav V. Reddy · 10 shared papers, 2021–2023 · strength 1.57
  17. Jacquelyn W. Zimmerman · 10 shared papers, 2021–2026 · strength 1.55
  18. Matthew John Weiss · 19 shared papers, 2015–2022 · strength 1.55
  19. William Reece Burns · 4 shared papers, 1 shared grant, 2021–2026 · strength 1.51
  20. Shuchi Sehgal · 10 shared papers, 2021–2023 · strength 1.46
  21. Nilofer Saba Azad · 8 shared papers, 1 shared grant, 2016–2025 · strength 1.46
  22. William R. Burns · 11 shared papers, 2021–2025 · strength 1.43
  23. Arsen Osipov · 10 shared papers, 2021–2026 · strength 1.42
  24. Ding Ding · 13 shared papers, 2018–2026 · strength 1.41
  25. Amy Hacker‐Prietz · 17 shared papers, 2013–2023 · strength 1.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.